WHO Adds Two Ebola Vaccine Candidates to Trial
The recommended candidates target Bundibugyo virus, the cause of the current outbreak in the Democratic Republic of the Congo.
Updated on Nov. 17, 2026 in COVID-19

Live Poll
Do you trust new vaccines to help bring serious outbreaks under control?
WHO expert groups recommended adding two Ebola vaccine candidates, ChAdOx1 and Moderna's mRNA-1469, to the Tumaini clinical trial in the Democratic Republic of the Congo. It is the first time vaccines designed specifically against Bundibugyo virus are being evaluated during an outbreak of the disease.
Why it matters
The recommendation followed review of available preclinical and early clinical evidence and extends a ring-vaccination trial already underway. Tumaini tests multiple candidates within one trial, so the expansion could speed comparison of vaccines against an outbreak strain.
The WHO advisory group recommended both candidates after reviewing preclinical and early clinical evidence, and the Tumaini trial currently has four vaccination rings in place with several more being prepared. Whether the candidates will be deployed depends on national approvals, and their protective effect against Bundibugyo virus has not yet been tested in an outbreak setting.
The players
World Health Organization
The United Nations agency that coordinates international responses to public health emergencies and issues global health guidance.
University of Oxford
The English public research university whose researchers co-developed the ChAdOx1 vaccine candidate with the Serum Institute of India.
Serum Institute of India
One of the world's largest vaccine manufacturers by volume, based in Pune, India, which co-developed the ChAdOx1 candidate.
Moderna
The American biotechnology company known for developing one of the first authorized mRNA COVID-19 vaccines, which developed the mRNA-1469 candidate.
Coalition for Epidemic Preparedness Innovations
An international partnership that funds the development of vaccines against emerging infectious disease threats.
The details
ChAdOx1, developed by the University of Oxford with the Serum Institute of India, and Moderna's mRNA-1469 were recommended for further clinical evaluation this week. The Institut National de Recherche Biomédicale is leading the vaccines trial, and rapid development of the candidates was made possible by investments from the Coalition for Epidemic Preparedness Innovations.
Timeline
This week: WHO's Technical Advisory Group on Candidate Vaccine Prioritization recommended both candidates.
Monday (week of November 17, 2026): Companies were informed of the recommendations.
Early 2027: Results from the vaccine trial are expected.
Health Landscape
The ring-vaccination approach tested in Guinea during the West Africa Ebola outbreak a decade ago is being extended here to a different virus strain. Adding candidates that target Bundibugyo virus shows the model can be applied across Ebola species rather than only the strain used in that earlier trial.
The candidates will only reach trial participants after national approvals are granted, so access in the Democratic Republic of the Congo and neighboring countries depends on those decisions. Anyone in an affected contact network would be enrolled through the ring-vaccination approach rather than receiving a vaccine on request.
The takeaway
Vaccine development against a specific outbreak strain can move from preclinical evidence to in-outbreak trials quickly when trial infrastructure already exists. The Tumaini model shows that testing several candidates within one ring-vaccination trial is a practical way to compare options during an active outbreak.
What happens next
Initial findings from the treatment trials are expected in the coming months, and results from the vaccine trial are expected in early 2027.
Further reading
For broader context on outbreak vaccine trials, see the COVID-19 section.
Source note: This article includes information reported by Hindustan Times.
Live Poll
Do you trust new vaccines to help bring serious outbreaks under control?







